Regulatory expectations for patient input in drug development have shifted from aspiration to documented methodology across three major jurisdictions.
News|Webcasts|November 19, 2024
Cardiac Monitoring Reinvented: AI, Safety, and the Data Impact
Author(s)AliveCor
Webinar Date/Time: Mon, Dec 2, 2024 11:00 AM EST
Explore the latest advancements in patient-centered solutions and electrocardiogram (ECG) technology that are transforming clinical trials. This fireside chat articulates how artificial intelligence (AI)-powered solutions and regulatory strategies are transforming cardiac safety, data integrity, trial efficiency, and clinical research practices for the future.
Register Free:
Join leading experts in a fireside chat webcast to explore how advanced electrocardiogram (ECG) technologies and artificial intelligence (AI) are reshaping clinical trials, enhancing both data accuracy and operational efficiency. Discover how patient-centered solutions address key challenges in cardiac safety, data integrity, and regulatory compliance, aligning with recent Food & Drug Administration (FDA) guidance and transforming trial success rates. This session offers real-world perspectives on the future of clinical trials, showing how these innovations can be seamlessly integrated into your research.
- Discover how advancements in AI-powered ECG technology are enhancing data collection and delivery, improving efficiency and accuracy in clinical trials.
- Learn about patient-centered solutions addressing key cardiac safety challenges, data integrity, and regulatory compliance.
- Gain insights into how these innovations align with recent FDA guidance and shape the future of clinical trials.
Key Learning Objectives
- Discover how AI-powered ECG technologies improve clinical trial data accuracy and operational efficiency
- Explore patient-centered monitoring solutions that address critical challenges in cardiac safety, data integrity, and regulatory compliance
- Learn how recent FDA guidance on digital health technologies and decentralized trials influences the adoption and implementation of advanced ECG monitoring in clinical research
Who Should Attend
- Chief medical officers
- Clinical operations leads
- Data management leads
- Regulatory affairs
- Patient engagement leads
- Clinical trial managers
Speakers:
David E. Albert, MD
Founder, Chief Medical Officer
AliveCor
David E. Albert, MD, an Oklahoma native, is a physician, inventor and serial entrepreneur who has developed life-saving technologies and products over the last 30 years, turning a number of those innovations into tech startups. Today, he is a founder of three technology companies, InnovAlarm, Lifetone Technology, and AliveCor. His previous startups include Corazonix Corp (sold to Arrhythmia Research Technology) and Data Critical (sold to GE). Dr. Albert left GE in 2004 as Chief Scientist of GE Cardiology to disrupt several new markets. His latest invention, AliveCor’s KardiaMobile personal ECG technology, became a global sensation via a YouTube Video in January 2011 around the Consumer Electronics Show and was featured on ABC, CBS, CNN and Fox News among many other media outlets. Dr. Albert has 32 issued US patents, a large number pending and several new “secret inventions” in development. He has authored or co-authored over 50 scientific abstracts and publications, principally in the cardiology literature. Dr. Albert has lectured at the Entrepreneurship programs at the MIT Sloan School and the University of Oklahoma. Dr. Albert graduated with Honors from Harvard College and from Duke University Medical School.
Dr. Todd Rudo
EVP and Chief Medical Officer
Clario
Dr. Todd Rudo is EVP and Chief Medical Officer at Clario, providing medical and scientific leadership across the organization. He has nearly 20 years of clinical cardiology and pharmaceutical research experience, with a career predominantly focused on drug safety.
Dr. Rudo has board certifications in cardiology, cardiac electrophysiology, nuclear cardiology, adult echocardiography and internal medicine. His team provides expert consulting to clients on scientific and regulatory strategy, and ensures Clario’s product portfolio is scientifically robust, generating high quality clinical trial endpoint data. Dr. Rudo has a particular interest in applying innovative technologies to improve the scientific rigor of clinical trials, while maintaining focus on the customer experience, including minimizing patient and site burden.
David Zied
Vice President
Global BioPharma
David is an experienced pharmaceutical executive with more than 25 years in sales, marketing and operational leadership roles with several of the world’s leading pharmaceutical companies, including GSK, BMS, Bayer and Eisai. After working across several therapeutic areas including neurology, mental illness, cardiology and 15+ years in oncology, David joined AliveCor from Novartis Oncology, where he was responsible for developing innovative digital solutions through strategic partnerships with startups, including AliveCor. As the VP of Global BioPharma Partnerships, David works closely with Pharma clients to develop clinical trial and focused solutions to enable brand growth and improve patient access worldwide.
Mark Matson
Senior Director, Sensor Cloud
Medidata Solutions
Mark is in his 30th year of drug development and is an SME in the use of Digital Health Technologies in clinical research. He holds a BS in Molecular and Cellular Biology and a Master’s in Business and has held positions in research, manufacturing, portfolio management, and business development in large pharma, biotech, CRO, and technology companies.
Register Free:
Related to this article
In this video interview, Amélie Lothe, global medical community head for rare epilepsies at UCB Pharma, explains why the full burden of developmental and epileptic encephalopathies extends far beyond clinical symptoms—and why endpoints must reflect what families are actually hoping for.
This episode of The Human Side of Clinical Trials, hosted by Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., and Kelly Ritch, chief operating officer of ArcheMedX, Inc., explores why training completion metrics like attendance and quiz scores fail to capture true study readiness, and how measuring both competence and confidence can reveal trial risks before enrollment even begins.
Clinical trials have spent decades perfecting data capture, but the execution layer underneath it, including decision workflows, data collection design, and lab connectivity, remains fragmented in ways that limit what AI can realistically deliver and that quietly compromise the scientific validity of the data itself.
In this video interview, Amélie Lothe, global medical community head for rare epilepsies at UCB Pharma, describes how shifting patient engagement from protocol review to endpoint selection transforms both the quality of trial data and the experience of participation.
In this video interview, Amélie Lothe, global medical community head for rare epilepsies at UCB Pharma, explains why genuine patient partnership begins before the protocol is written—and what it looks like when patients and caregivers tell you a trial was designed with them in mind.
Participant engagement depends more on clarity and understanding than on gamification or incentives, requiring engagement embedded into trial workflows as a core design component rather than a peripheral consideration
Patient-centricity remains largely consultative in most clinical research, yet rare disease communities demonstrate that genuine partnership from protocol inception improves feasibility, reduces unnecessary burden, and identifies outcomes that matter to patients themselves.